A Multicenter Phase II Study with Triptorelin (Sustained-Release LHRH Agonist) in Advanced or Recurrent Endometrial Carcinoma: A French Anticancer Federation Study

Lhommé, C.; Vennin, P; Callet, Nasrine; Lesimple, Thierry; Jl, Achard; Chauvergne, J; Luporsi, É.; Chinet-Charrot, P.; Coudert, Bruno; Couette, J.E.; Guastalla, Jean Paul; Lebrun, D.; Ispas, S; Blumberg, Joëlle

doi:10.1006/gyno.1999.5538

Cited by 42 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also tamoxifen and anastrozole should be probably more considered in those patients, taking into account the above-described disease molecular patterns (52,53) .…”

Section: Endometrial Cancermentioning

confidence: 98%

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

Basile

Angioli

Manci

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

The epidemiologic pattern of cancers in developing countries differs in many aspects from that of industrialized nations. Cancer natural history, microbiologic environment, patient's immune system, and drug availability may differ as well. Four of five new cases of cervical cancer and most of cervical cancer deaths occur in developing countries. Where chemoradiation and supportive care facilities are unavailable, it would be logical to consider an inexpensive effective drug. In locally advanced cases, neoadjuvant chemotherapy followed by surgery should be considered the treatment of choice. For ovarian cancer, it may be reasonable to maintain a secure supply of platinum and/or taxanes. For endometrial cancer, platinum compounds are proved active chemotherapic single agents. Oral medroxyprogesterone acetate (MPA) may represent a good chance for treating an advanced or recurrent disease. For vulvar/vaginal cancer, the role of chemotherapy alone is currently considered limited, and it is mostly used as palliative treatment in advanced or recurrent cases. Whenever possible, standard western chemotherapic regimens should be applied in developing countries as well. When standard therapies are unavailable, drugs of choice should be easily accessible, inexpensive, and effective. The most commonly used drugs are cisplatin, cyclophosphamide, and MPA.

show abstract

“…Also tamoxifen and anastrozole should be probably more considered in those patients, taking into account the above-described disease molecular patterns (52,53) .…”

Section: Endometrial Cancermentioning

confidence: 98%

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

Basile

Angioli

Manci

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Conflicting results emerged from these studies. In fact, Davies et al [36], Lhommé et al [41], and Jeyarajah et al [42] showed evidence of efficacy in long-term treatments, with response rate ranging from 9% to 57%. On the other hand, Covens et al [43], Markman et al [44], and Asbury et al [45] observed insufficient activity.…”

Section: Therapeutical Perspectivesmentioning

confidence: 99%

The LH/hCG Axis in Endometrial Cancer: A New Target in the Treatment of Recurrent or Metastatic Disease

Arcangeli

Noci

Fortunato

et al. 2010

Obstetrics and Gynecology International

View full text Add to dashboard Cite

Endometrial cancer (EC) is a hormone-dependent cancer that currently represents the most frequent malignancy of the female reproductive tract. The involvement of steroid hormones in EC etiology and progression has been reported. More recently, gonadotropins, and, in particular LH/hCG, are emerging as novel regulators of tumor progression. In the present review, we discuss the role of the LH/hCG axis (i.e. LH/hCG and its receptors, LH/hCG-R) in both gonadal and nongonadal tissues, in physiological and neoplastic conditions. In cancer cells, LH/hCG mainly controls cell proliferation and apoptosis. In particular, in EC LH/hCG improves cell invasiveness, through a mechanism which involves the LH/hCG-R, which in turn activate protein kinase A and modulate integrin adhesion receptors. Indeed, the LH/hCG-R mRNA is expressed in primary ECs and this expression correlates with LH/hCG-induced cell invasiveness in vitro. These results lead to hypothesize that recurrent and metastatic ECs, which express LH/hCG-R, could benefit from therapies aimed at decreasing LH levels, through Gn-RH analogues. Hence, the LH/hCG axis could represent a prognostic factor and a new therapeutic target in EC.

show abstract

“…Application of long-acting analogues such as D-Trp 6 -GnRH-I superagonist (1,2) in second-line therapy for ovarian cancer (3), uterine cancer (4), and premenopausal breast cancer (5,6) has been studied in small (3,4) or moderately sized clinical trials (2) since the late 1980s. Larger data sets indicate that a relatively poor, widely variable, yet favorable additive effect on response rates can occur when GnRH is used in combination therapy (5,6).…”

Section: Introductionmentioning

confidence: 99%

Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to AgonistIn vitroandIn vivo

et al. 2008

View full text Add to dashboard Cite

Activation of gonadotropin-releasing hormone (GnRH) receptors inhibits proliferation of transformed cells derived from reproductive tissues and in transfected cell lines. Hence, GnRH receptors represent a therapeutic target for direct action of GnRH analogues on certain proliferating cells. However, more cell biological data are required to develop this particular application of GnRH analogues. Therefore, we compared the effects of GnRH receptor activation in transfected HEK293 cells (HEK293 [SCL60] ) with transfected human ovarian cancer cell lines SKOV3 and EFO21, human hepatoblastoma HepG2 cells, and rat neuroblastoma B35 cells. Marked differences in receptor levels, magnitude of inositol phosphate generation, and dynamics of inositol phosphate turnover occurred in the different cells. Activation of GnRH receptors, expressed at high or moderate levels, inhibited the growth of HEK293 [SCL60] and B35 cells, respectively. Western blotting detected markers of apoptosis [cleaved poly(ADP-ribose) polymerase, caspase-9] in HEK293 [SCL60] and B35 following treatment with 100 nmol/L D-Trp 6 -GnRH

show abstract

A Multicenter Phase II Study with Triptorelin (Sustained-Release LHRH Agonist) in Advanced or Recurrent Endometrial Carcinoma: A French Anticancer Federation Study

Cited by 42 publications

References 21 publications

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting

The LH/hCG Axis in Endometrial Cancer: A New Target in the Treatment of Recurrent or Metastatic Disease

Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to AgonistIn vitroandIn vivo

Contact Info

Product

Resources

About